How much will a box of Alpelisib cost in 2025?

Alpelisib (Alpelisib) is a targeted drug used to treat specific types of breast cancer. It has not yet been officially launched in mainland China. This means that domestic patients are temporarily unable to purchase the drug directly through hospitals or pharmacies, nor can they enjoy the medical insurance reimbursement policy. Therefore, many patients can only rely on overseas channels to obtain this drug, or obtain it through third-party purchasing agents.

According to current market information, the price of the Indian version of Apelis’ original drug is more than 3,000 yuan per box. This version is launched in India by the original pharmaceutical manufacturer. Its quality and efficacy are consistent with those on the European and American markets. However, due to the relatively low production location and distribution costs, the price is relatively cheaper. For patients who want to use original drugs but are constrained by budget, the Indian version of original drugs is a viable option.

At the same time, generic versions of Apelvis also appeared on the market. Taking the generic version produced by a Lao pharmaceutical factory as an example, a box of 150mg sells for about more than 1,000 yuan. Such generic drugs are usually consistent with the original drugs in terms of drug ingredients and dosage, and have clinical use experience in overseas markets, making them an important alternative for patients with limited budgets.

Generally speaking, Apelis has been sold in multiple versions in overseas markets, with prices ranging from more than 1,000 yuan to more than 3,000 yuan. Although brand-name drugs are more expensive, generic drugs can meet most treatment needs. In the future, if the drug is marketed in China and included in medical insurance, its accessibility and patients' economic burden may be further improved.

Reference materials:https://www.drugs.com/